help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH

Published ahead of print on September 16, 2004, doi:10.1164/rccm.200310-1349OC

Am. J. Respir. Crit. Care Med., Volume 170, Number 12, December 2004, 1302-1309

A more recent version of this article appeared on December 15, 2004
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
200310-1349OCv1
170/12/1302    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Scanlon, P. D
Right arrow Articles by The Lung Health Study Research Group,
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Scanlon, P. D
Right arrow Articles by The Lung Health Study Research Group,

Submitted on October 2, 2003
Accepted on September 13, 2004

Loss of Bone Density with Inhaled Triamcinolone in Lung Health Study II

Paul D Scanlon1, John E Connett2*, Robert A Wise3, Donald P Tashkin4, Thelma Madhok2, Melissa Skeans2, Paul C Carpenter5, William C Bailey1, A. Sonia Buist6, Michael Eichenhorn7, Richard E Kanner8, Gail Weinmann9, and The Lung Health Study Research Group

1 Department of Medicine, Mayo Clinic, Rochester, MN, USA, 2 Department of Biostatistics, University of Minnesota Coordinating Center, Minneapolis, MN, USA, 3 Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA, 4 Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA, 5 Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA, 6 Department of Medicine, Oregon Health Sciences University, Portland, OR, USA, 7 Department of Medicine, Henry Ford Hospital, Detroit, MI, USA, 8 Department of Medicine, University of Utah, Salt Lake City, UT, USA, 9 Lung Division, National Heart, Lung, and Blood Institute, Bethesda, MD, USA

* To whom correspondence should be addressed. E-mail: john-c{at}blueox.ccbr.umn.edu.

Inhaled glucocorticosteroids (ICS) are commonly prescribed for chronic obstructive pulmonary disease (COPD). No adverse effect on bone mineral density (BMD) has been proven. In a randomized double-blind, placebo-controlled trial at 7 centers in North America, we recruited 412 current smokers or recent quitters with mild-to-moderate COPD. They used inhaled triamcinolone acetonide, 600 mcg, or placebo, twice daily. We measured femoral neck and lumbar spine BMD at baseline and after 1 and 3 years, and serum osteocalcin at baseline, 3 months, one year, and 3 years. After three years, BMD at the femoral neck decreased 1.78% more with ICS than with placebo (p < 0.001). More participants in the ICS group experienced ≥6% loss of femoral neck BMD (p = 0.002). Lumbar spine BMD increased in the placebo group by 0.98%; but decreased by 0.35% in the ICS group (a difference of 1.33%, p = 0.007). Changes in osteocalcin did not correlate with changes in BMD. Fractures, lost height, or osteoporosis diagnoses were not increased among ICS users compared with placebo users. In summary, use of inhaled triamcinolone acetonide was associated with loss of BMD at the femoral neck and lumbar spine after 3 years of treatment.


Key words: bone density, clinical trials, double-blind method, forced expiratory volume, obstructive lung diseases




This article has been cited by other articles:


Home page
ANN INTERN MEDHome page
S. D. Aaron, K. L. Vandemheen, D. Fergusson, F. Maltais, J. Bourbeau, R. Goldstein, M. Balter, D. O'Donnell, A. McIvor, S. Sharma, et al.
Tiotropium in Combination with Placebo, Salmeterol, or Fluticasone Salmeterol for Treatment of Chronic Obstructive Pulmonary Disease: A Randomized Trial
Ann Intern Med, April 17, 2007; 146(8): 545 - 555.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
I. M. Balfour-Lynn, B. Lees, P. Hall, G. Phillips, M. Khan, M. Flather, J. S. Elborn, and on behalf of the CF WISE (Withdrawal of Inhaled St
Multicenter Randomized Controlled Trial of Withdrawal of Inhaled Corticosteroids in Cystic Fibrosis
Am. J. Respir. Crit. Care Med., June 15, 2006; 173(12): 1356 - 1362.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
L. Fabbri, S. P. Peters, I. Pavord, S. E. Wenzel, S. C. Lazarus, W. MacNee, F. Lemaire, and E. Abraham
Allergic Rhinitis, Asthma, Airway Biology, and Chronic Obstructive Pulmonary Disease in AJRCCM in 2004
Am. J. Respir. Crit. Care Med., April 1, 2005; 171(7): 686 - 698.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2004 American Thoracic Society
  ATS Sleep Tracings Quiz